Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export strategy, targeting markets in the Gulf Region and South East Asia.
Production costs are rising, and pricing pressures continue, so the margins in the industry are still very low
Dr Hany Mashaal, general manager for Egypt and the Rest of Middle East for Sun Pharma, explains the importance of Egypt for the Indian company, having recently opened a manufacturing…
Amre Mamdouh, vice president & area general manager for Egypt and North Africa at GSK, explains how GSK has been able to hold its leadership position in Egypt despite economic…
Khaled Atef Elmounayri, country manager of AstraZeneca Egypt, reveals how AstraZeneca has remained the fastest-growing multinational pharmaceutical company for five years straight in Egypt, despite facing economic difficulties and pricing…
As of today, the Evergreen boat that blocked global shipping when it got stuck in the Suez Canal has still not been allowed to leave Egypt. The infamous episode illustrated…
The latest Middle East and North Africa (MENA) pharma, including Egypt’s opening of the largest “pharmaceutical city” in the Middle East and Abu Dhabi’s quest to become a pharma hub…
The latest news from Middle East & North African pharma, including Pfizer’s transformation of its Saudi operations; why India is calling for reform of the import process for pharma products…
See our Cookie Privacy Policy Here
